News

Here you will find our latest news and updates.

September 2019 updates to website

Uncategorized

The website has now been updated following September’s LSCMMG

The following drugs have been added/updated:

Ciclosporin 0.1% / 1 mg/mL eye drops (Verkazia®) — Severe vernal keratoconjunctivitis in children from 4 years of age and adolescents

Azelastine hydrochloride/Fluticasone propionate 137mcg/50mcg (120d) (Dymista ®) — Relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.

Fluocinolone Acetonide —  Intravitreal implant for treating recurrent noninfectious uvetitis (NICE TA590)

Risankizumab — For treating moderate to severe plaque psoriasis (NICE TA596)

Dapagliflozin — Dapagliflozin with insulin for treating type 1 diabetes (NICE TA 597)

The following guidelines have been added/updated:

Vitamin D (Version 3.0) — Position Statement — Update

Camouflaging Products (Version 1.1) — Position Statement — Update

Trans Female Gender Dysphoria (Version 1.1) — Prescribing Information Sheet — Update

Combined Adult and Child ADHD (Version 1.1) — Guideline — Update

Psoriasis — LSCMMG Biologic & High Cost Drugs Commissioning Pathway (Version 1.6) — Guideline — Update

Home Monitoring of Blood Glucose Levels  — Guideline — Update